Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26631
IPSCIO Record ID: 263771
The patents relate to Peginesatide.
Peginesatide shall mean Licensees proprietary compound known as peginesatide, including any derivative, fragment, variant, prodrug, metabolite, degradation product, oxidation product, ester, stereoisomer, hydrate, solvate, salt form or radio-labeled form thereof.
IPSCIO Record ID: 4553
TARGTEPO is an endogenous Erythropoietin (EPO) secretion TARGT for treatment of End-Stage Renal Disease (ESRD) and other indications requiring EPO treatment such as ÃŸ-thalassemia. Erythropoietin (EPO) is a protein that is naturally secreted by the kidneys and functions to stimulate the bone marrow to produce red blood cells. End-Stage Renal Disease (ESRD) is a condition where the kidneys have completely stopped functioning.
IPSCIO Record ID: 26640
Â·Recombinant Human Interferon alpha-2a (rHulFN-a 2a) and alpha-2b (rHulFN-a 2b)
Â·Recombinant Human granulocyte colony stimulating factor (rHuG-CSF);
Â·Recombinant Human granulocyte macrophage colony stimulating factor (rHuGM-CSF);
The Company has acquired license to patented technologies related to the production of therapeutic proteins, alpha and beta interferon, Interleukin 2, EPO (erythropoietin) and human growth factors (rHuG-CSF and rHuGM-CSF).
IPSCIO Record ID: 27386